Direxion S&P Biotech Bear 3X

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SVRA

LABU

LABD

SBIO

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

StockTitan

Savara

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

00945

Manulife Singapore will launch the Shield™ multi-cancer detection test in May 2026 through its partnership with Guardant Health, becoming the first in Singapore to offer this blood test for multiple cancers. This initiative supports preventive healthcare, addressing the rising demand for early cancer detection. The Shield™ test has received Breakthrough Device Designation from the FDA and was recognized as Oncology Product Innovation of the Year. Manulife aims to empower customers in managing their health and finances.

Singapore Business Review

Guardant Health

MANULIFE-S

Manulife Financial

Ark Genomic Revolution ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Medical Service ETF

China Merchants CSI Biotechnology Theme ETF

Manulife Singapore to offer multi-cancer blood test starting May

IVVD

IBBQ

Invivyd (NASDAQ:IVVD) reported a quarterly EPS of ($0.13), missing estimates by ($0.05), with revenue of $13.74 million below the expected $18.04 million. The company has a negative return on equity of 48.65% and a net margin of 98.25%. Despite challenges, Invivyd's VYD2311 study is progressing well, and PEMGARDA revenue grew 22% year-over-year. Shares fell 21.1% to $1.16, with significant insider selling noted. Institutional investors have increased their stakes, with 70.36% of shares held by hedge funds.

Market Beat

Invivyd

VG Health

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Health Care Select Sector SPDR

Invivyd (NASDAQ:IVVD) Issues Earnings Results

GRI Bio reported promising Phase 2a data for its IPF candidate GRI-0621, showing significant improvements in clinical symptoms and safety compared to standard antifibrotics. The company ended Q1 2026 with $11 million in cash and narrowed its net loss to $2 million. Analysts rate GRI stock as a Buy with a $10 target, though concerns about financial performance and technical indicators persist. GRI Bio focuses on therapies for inflammatory and autoimmune diseases, with a pipeline aimed at immune modulation.

Tip Ranks

GRI Bio

GRI Bio Highlights Promising Phase 2a IPF Data, Outlook

RGNX

Bank of America has lowered its price target for REGENXBIO (NASDAQ:RGNX) from $25.00 to $14.00 while maintaining a 'buy' rating. The new target suggests a potential upside of 139.93%. Other analysts have also adjusted their ratings, with a consensus price target of $23.91. REGENXBIO's stock is currently trading at $5.84, down 6.5%, with a market cap of $301.20 million. The company reported a loss of $1.72 EPS in its last earnings report, missing expectations significantly.

Regenxbio

Bank of America

Morgan Stanley

State Street

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

State Street® US Equity Premium Inc ETF

Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price

GOVX

GeoVax Labs (NASDAQ:GOVX) stock is down 13.57% in premarket trading after an 80% rally, following the announcement of a $3M private placement, raising concerns over shareholder dilution. The offering includes approximately 2.03 million shares and warrants for an additional 4.05 million shares. Despite the drop, the stock remains above its 20-day and 50-day SMAs, but is significantly below its 100-day and 200-day SMAs, indicating a long-term downtrend.

benzinga_article

GeoVax Labs

Shutterstock

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

Why Is GeoVax Labs Stock Falling Tuesday?

ARWR

Arrowhead Pharmaceuticals Director Hongbo Lu sold 2,970 shares at $76.88 each, totaling $228,333.60, reducing his stake by 5.40%. Post-sale, he holds 52,012 shares valued at approximately $3.99 million. The transaction was disclosed to the SEC and executed under a Rule 10b5-1 plan. The stock recently traded up 2.3% to $79.69, with a market cap of $11.23 billion and a negative earnings per share of -$0.93 for the last quarter.

ArrowHead Pharma

Bank of Nova Scottia

JPMorgan Chase

ROYAL BANK OF CANADA

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock

MEDP

IDNA

A class action lawsuit has been filed against Medpace Holdings Inc. for securities fraud, alleging misrepresentations regarding cancellation rates and book-to-bill ratios, leading to a 16% stock drop. Investors are urged to act by June 8, 2026, to be appointed as lead plaintiffs. The case is pending in the U.S. District Court for the Southern District of Ohio.

prnewswire

Medpace

iShares US Healthcare Providers

iShares Genomics Immunology and Healthcare ETF

SPDR S&P Health Equip

iShares US Medical Devices

Tesla

Teva Pharmaceutical Industries

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

CMND

Clearmind Medicine Inc. (CMND) has announced a 1-for-10 reverse stock split effective May 21, 2026, to comply with Nasdaq's minimum bid price requirement. This will reduce its outstanding shares from 10,190,337 to approximately 1,019,033. The company's authorized share capital remains unchanged. Currently, CMND shares are trading at $0.23, down 38.02%.

nasdaq

Clearmind Medicine

Nasdaq

Clearmind Medicine Announces 1-for-10 Reverse Stock Split; Stock Down

LEGN

Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Despite this, the stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets, with RBC Capital raising its target from $62 to $64, Morgan Stanley lowering it from $49 to $48, and TD Cowen increasing it from $21 to $29. CEO Ying Huang emphasized the company's growth and path toward sustainable profitability.

Legend Biotech

Toronto Dominion Bank

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results

Direxion S&P Biotech Bear 3X(LABD.US)

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

Manulife Singapore to offer multi-cancer blood test starting May

Invivyd (NASDAQ:IVVD) Issues Earnings Results

GRI Bio Highlights Promising Phase 2a IPF Data, Outlook

Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price

Why Is GeoVax Labs Stock Falling Tuesday?

Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

Clearmind Medicine Announces 1-for-10 Reverse Stock Split; Stock Down

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results